ストックスクリーナーアプリを入手
18.33
6.10%
-1.19
アフターアワーズ：
18.68
0.35
+1.91%
Celldex Therapeutics Inc (CLDX) 最新ニュース
UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating - marketscreener.com
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Report | CLDX Stock News - GuruFocus
Celldex: Q1 Earnings Snapshot - New Haven Register
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Celldex Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Loss $0.81 Per Share, vs. FactSet Est of $-0.75 - marketscreener.com
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - Bluefield Daily Telegraph
Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX
Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - The Manila Times
New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan
Celldex: Q4 Earnings Snapshot - Barchart.com
Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX
A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News
Invesco Ltd. Has $1.06 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics Inc’s results are impressive - uspostnews.com
The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com
Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com
Canaccord Initiates Coverage on Celldex (CLDX) with a Positive O - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Celldex Therapeutics Inc [CLDX] Records 200-Day SMA of $28.24 - knoxdaily.com
Regeneron Pharmaceuticals, Inc [REGN] Shares Rise 0.40 % on Wednesday - knoxdaily.com
How to interpret Celldex Therapeutics Inc (CLDX)’s stock chart patterns - uspostnews.com
Chronic Spontaneous Urticaria Market Set for Robust Growth From - openPR.com
Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (NASDAQ:CLDX) - Seeking Alpha
Commit To Purchase Celldex Therapeutics At $15, Earn 20.1% Annualized Using Options - Nasdaq
Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight - openPR.com
Vanguard Group Inc. Acquires 12,213 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $14.57 amid market challenges - Investing.com Australia
Celldex stock touches 52-week low at $14.57 amid market challenges By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Takes $306,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Corebridge Financial Inc. Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Detailed In New Research Report - openPR.com
Celldex Therapeutics Enters Oversold Territory (CLDX) - Nasdaq
Teacher Retirement System of Texas Buys 2,819 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex stock touches 52-week low at $18.52 amid market challenges - Investing.com Philippines
Celldex stock touches 52-week low at $18.52 amid market challenges By Investing.com - Investing.com South Africa
When (CLDX) Moves Investors should Listen - news.stocktradersdaily.com
Swiss National Bank Increases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Global Cholera Vaccines Market Business Outlook ,Growth - openPR.com
Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):